Fusion Antibodies plc Announces Formation of New Scientific Advisory Panel

Fusion Antibodies Announces Formation of Scientific Advisory Panel

World-renowned experts in the fields of antibody engineering, immunoinformatics and drug selection and services Matthew Baker Ph.D., Professor Terry Rabbitts, and Professor Charlotte Deane to join Fusion Antibodies plc Scientific Advisory Panel

Fusion Antibodies plc (“Fusion”), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the formation of a new Scientific Advisory Panel (the “SAP”) of leading experts to support the Company’s research and development across its range of antibody services, and to provide advice regarding emerging science and technology issues and trends.

This eminent group of leading experts and thought leaders will play a key role in helping to shape the Company’s services and commercial roadmap, strategy and R&D activities.

The first additions to the panel are:  Matthew Baker Ph.D., Professor Terry Rabbitts and Professor Charlotte Deane.

Matthew Baker, PhD has more than 20 years’ experience developing biologics in biotech and pharma companies and is a research expert in B- and T-cell immunology, including drug immunogenicity. He was the Chief Scientific Officer of Abzena until 2016 and previously held a Non-Executive Director role at Oxgene. He is currently the CEO of NeoPhore, a private company focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Matthew brings detailed immunology and virus-based mammalian display knowledge to the SAP as well as industry and market insight.

Professor Terry Rabbitts is a Professor of Immunology at the Institute of Cancer Research in London (UK), where he focuses on developing technologies using intracellular antibody fragments and small molecule derivatives, mainly aimed at targeting chromosomal translocation protein products. Terry is the ex-Chair of Cambridge Antibody Technology’s Scientific Advisory Board, holding this position from launch until its IPO on the London Stock Exchange and is currently an advisor to several start-up biotech companies. He is also co-founder of both Orbit Discovery and Quadrucept Bio Ltd.

Professor Charlotte Deane is a Professor of Structural Bioinformatics at the University of Oxford. Her research in the Oxford Protein Informatics Group covers several areas in protein structure and interaction networks, combining both theoretical and empirical analysis. Her detailed expertise means she will bring structural modelling, bioinformatics and library design experience to the SAP, as well as an insight key to the development of future machine learning algorithms.

It is truly an honour to announce these distinguished and prominent experts as new members of Fusion’s Scientific Advisory Panel,” said Richard Jones Ph.D., Chief Executive Officer of Fusion Antibodies. “The appointment of these three industry experts adds a depth of expertise to our newly created SAP who will provide Fusion with relevant and informed technical and scientific counsel and broadens our access to a network of clinical and scientific advisors, as well as academic collaborators. Each member brings unique qualities to Fusion, and we are looking forward to drawing on their individual experiences as we continue our research and development programs and pipeline. We are delighted to welcome them to the team.”

The establishment of this prominent SAP truly underlines Fusion’s commitment to driving pioneering scientific and technical innovation, responding to the evolving needs of it’s clients through sustained investment in R&D programs, platforms and pipeline.